CIBC Asset Management Inc Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

CIBC Asset Management Inc lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 34,386 shares of the biopharmaceutical company's stock after buying an additional 1,034 shares during the quarter. CIBC Asset Management Inc's holdings in Regeneron Pharmaceuticals were worth $24,494,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of REGN. Rakuten Securities Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 19 shares during the period. FSA Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at about $26,000. Fairfield Financial Advisors LTD purchased a new position in Regeneron Pharmaceuticals during the third quarter worth about $37,000. Private Wealth Management Group LLC boosted its holdings in Regeneron Pharmaceuticals by 260.0% during the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 39 shares during the last quarter. Finally, Truvestments Capital LLC bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth about $39,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock traded up $4.31 on Friday, hitting $700.33. 727,332 shares of the company traded hands, compared to its average volume of 923,518. Regeneron Pharmaceuticals, Inc. has a 12-month low of $642.00 and a 12-month high of $1,211.20. The firm's 50-day simple moving average is $699.40 and its 200 day simple moving average is $883.75. The company has a market cap of $76.56 billion, a P/E ratio of 18.29, a P/E/G ratio of 2.30 and a beta of 0.08. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter last year, the business posted $11.86 earnings per share. The company's revenue for the quarter was up 10.3% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a $0.88 dividend. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.50%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on REGN. StockNews.com downgraded Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Monday, November 4th. Barclays decreased their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating for the company in a research report on Friday, November 1st. Robert W. Baird reduced their price target on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating for the company in a research report on Wednesday, February 5th. Bernstein Bank lowered their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Finally, Canaccord Genuity Group assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price for the company. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.